2016
Biotransformation and Rearrangement of Laromustine
Nassar AE, Wisnewski AV, King I. Biotransformation and Rearrangement of Laromustine. Drug Metabolism And Disposition 2016, 44: 1349-1363. PMID: 27278961, DOI: 10.1124/dmd.116.069823.Peer-Reviewed Original ResearchConceptsNuclear magnetic resonance spectroscopyCollision-induced dissociationFourier transform ion cyclotron resonance mass spectrometerIon cyclotron resonance mass spectrometerAccurate mass measurementsMass spectrometry studiesHydrogen-deuterium exchangeMagnetic resonance spectroscopyMass spectral rearrangementsExact massSpectrometry studiesEnzyme catalysisReactive intermediatesMass spectrometerDecomposition productsResonance spectroscopyConjugation reactionsElemental compositionPossibility of rearrangementMass measurementsSpectral rearrangementsDissociationRadioactive componentsLoss of nitrogenMetabolite products
2015
Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats
Nassar AF, Wisnewski A, King I. Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats. Xenobiotica 2015, 45: 711-721. PMID: 25798740, PMCID: PMC4681490, DOI: 10.3109/00498254.2015.1016475.Peer-Reviewed Original ResearchConceptsQuantitative whole-body autoradiographyBolus doseDrug-derived radioactivityPeak plasma concentrationWhole-body autoradiographyGroup 1 animalsUrinary bladder contentsLong-Evans ratsExcretion of drugsSmall intestine contentsRecovery of radioactivityNovel sulfonylhydrazineAnti-cancer agentsSpinal cordMale ratsPlasma concentrationsIntravenous administrationRenal cortexBladder contentsTotal bodyMetabolic dispositionOrgan exposureSmall intestineRatsMedical guidelines